Jago Grahak Jago

Edit Template

January 2026

Budget 2026–27: Beyond Insurance to a Universal Health Coverage for All

Why India must move from fragmented schemes to a rights‑based health system Promise of Universal Health Coverage: Universal Health Coverage (UHC), as defined by the World Health Organization, means that all individuals and communities can access quality health services without suffering financial hardship. In India, this remains an unfinished agenda. More than 20 million citizens are pushed below the poverty line each year due to unaffordable healthcare costs and poor access to timely, quality primary care. While schemes such as Ayushman Bharat–PMJAY, the Central Government Health Scheme (CGHS), and the Employees’ State Insurance Corporation (ESIC) have expanded coverage, healthcare financing remains fragmented, insurance‑heavy, and dependent on out‑of‑pocket spending. The result is inequity, cost escalation, and persistent gaps in access, especially for informal workers, senior citizens, and the near‑poor. The Union Budget 2026–27 is the most powerful instrument available to the Government of India to transition from scheme‑based financing to a rights‑based framework. This year’s budget must move decisively beyond insurance to build a universal healthcare system that treats health as a public good and a constitutional responsibility. Raising Public Health Expenditure: The first step toward UHC is a clear fiscal commitment. India must announce a time‑bound roadmap to raise combined Central and State public health expenditure to at least three percent of GDP. Without strong tax‑funded public systems, universal coverage will remain aspirational. Enhanced untied grants and incentive‑based transfers to States are essential to strengthen delivery capacity. Such a commitment would signal political will and institutional seriousness, aligning India with global best practices. Strengthening Infrastructure and Service Delivery: Incremental health spending must prioritize the public backbone of healthcare. Government hospitals, medical colleges, urban and rural primary health centres, public diagnostics, essential medicines, and human resources need sustained investment. At least sixty percent of additional allocations should be directed toward strengthening public capacity rather than insurance reimbursements. When public facilities are well‑equipped and staffed, they become the first point of care for millions, reducing dependence on expensive private providers and ensuring equitable access. Reforming Ayushman Bharat–PMJAY: Ayushman Bharat–PMJAY has been a landmark initiative, but its poverty‑based targeting limits its reach. The scheme must evolve into a progressive UHC platform that includes informal workers, near‑poor households, and senior citizens. Budgetary clarity is needed on coverage expansion, accompanied by expenditure rationalisation and quality safeguards. Strong cost controls, standard treatment guidelines, and pricing transparency must be introduced to prevent misuse and ensure value for public money. PMJAY must also expand beyond hospitalization to cover outpatient care, diagnostics, and chronic disease management. Converging ESIC and CGHS: India’s healthcare financing landscape is riddled with duplication. ESIC and CGHS serve overlapping populations but operate in silos. The Budget should announce a National Health Financing Convergence Framework to integrate these schemes with PMJAY. Accumulated ESIC surpluses can be used to upgrade ESIC hospitals and strategically purchase healthcare services. Administrative and digital convergence will eliminate inefficiencies, promote equity, and simplify access for beneficiaries. Regulating Private Health Insurance: Private health insurance plays a growing role in India’s healthcare ecosystem, but it must be regulated in the public interest. The Budget should introduce stronger consumer protection norms, including standardized exclusions and disclosures, limits on arbitrary claim rejections, and grievance redressal mechanisms with strict timelines. Zero‑rating GST on health insurance premiums would improve affordability and signal that insurance is a form of social protection, not merely a commercial product. Regulation must ensure that insurance serves the consumer, not the insurer only. Investing in Prevention and Primary Care: Prevention is the most cost‑effective and equitable pathway to UHC. The Budget must create dedicated lines for non‑communicable disease prevention, nutrition and maternal health, mental health services, and environmental and climate‑linked health risks. Linking a portion of Central transfers to preventive health outcomes would incentivize States to invest in long‑term resilience. Primary care must be the foundation of India’s health system, not an afterthought. By investing in prevention, India can reduce future costs, improve population well‑being, and build a healthier workforce. We must focus on the expansion of Health & Wellness Centres, which was an important vertical under the Ayushman Bharat Scheme. Expected Outcomes: If implemented, these measures will reduce catastrophic out‑of‑pocket expenditure, improve equity and accessibility across income groups, strengthen public institutions, contain healthcare inflation, and move India decisively toward Universal Health Coverage. The benefits will be felt not only in hospitals and clinics but also in households, workplaces, and communities. A rights‑based approach to health will enhance economic productivity, as healthy citizens are better able to work, learn, and contribute. Appeal: A Budget That Counts for Health: The Union Budget 2026–27 must be judged not only by fiscal prudence but by its commitment to human dignity. Healthcare is not just another sector—it is the foundation of productivity, prosperity, and national resilience. Universal Health Coverage will not be achieved through incremental tweaks. It requires bold fiscal commitment, public system strengthening, and citizen‑centric regulation. India does not need a budget that merely allocates for health. It needs a budget that guarantees it.

Budget 2026–27: Beyond Insurance to a Universal Health Coverage for All Read More »

INTERVIEW : Nakul Pasricha

Nakul Pasricha President and CEO of Pharma Secure Mr Nakul Pasricha is a passionate advocate of making pharmaceutical supply chains safer through standards-led authentication and traceability solutions. He is the President and CEO of Pharma Secure, a global leader in pharmaceutical supply chain traceability and serialisation with the end goal of enabling safety and authenticity in pharmaceuticals. It works with leading pharmaceutical makers to track and verify their supply chains and ensure the authenticity of their drugs. Mr Pasricha has also served as the President of the Authentication Solution Providers' Association (ASPA) from 2019 to 2023 and continues to be a member of its Governing Body. ASPA is a non-profit based in Delhi that works against counterfeiting in India, by building authentication eco-systems. We present an interview with Mr Pasricha as sourced from www.indiaspend.com/. When we talk about spurious drugs in India, what are we talking about? The CDSCO’s 2009 study was the first such comprehensive study that was done in India to measure the extent of spurious and substandard drugs. It was conducted again, as an update, in 2015. The outcome was similar, where they found about 0.3% of drug samples to be spurious and about 3% to be substandard. However, other studies have been done, including a comprehensive study around the world by the WHO in 2018, which found one out of every 10 drugs sampled [in low- and middle-income countries] to be spurious (which they call falsified), or substandard. So, it is a tremendous problem. Other estimates are as high as 20%, or 30%. ASPA conducted our own meta study, where we just looked at reports of incidents of spurious or substandard drugs in India, and at the number of such reports across the country. That number jumped by 47% from 2020 to 2021, which is the last year for which we have data with us. So, this problem has been brewing. And it is a problem that I believe has been, at least domestically, not given the importance and the attention that it needs in order to save patients' lives. What does that translate into, let's say in terms of the number of samples in any study? We didn't do our own sampling. We just looked at the media reports of such incidents that were coming out independently, where it had been discovered, catalogued and reported that spurious or substandard drugs were being sold in the market. Just by that number, you can see that the percentage is increasing. To get an accurate number across the length and breadth of India is, of course, a big challenge, which is why the CDSCO study stands there. There have been other researchers that have come to India and conducted studies and found up to 10% of the samples that they checked were substandard. But it's been over a decade since such a study was done. When you say 'spurious' and 'substandard', do these terms go together? Or is there a distinction between the two? That's right. This problem is very important. It used to be that you would just call [spurious drugs] counterfeit. But counterfeit as a term can also be mixed up with the intellectual property rights issue, which is well documented. So, 'spurious' really means a drug that is falsely labelled, to position it or represent it as being made by a genuine manufacturer. It will often not have any active pharmaceutical ingredient in it, it will not be effective, and it will be something that is intended to deceive the buyer or the patient. 'Substandard' is something that typically will be from the manufacturer that it claims to be from, but may not have the right quality of or enough ingredients, so its efficacy is under question. The CDSCO study had found just 11 samples out of 23,000+ samples to be spurious, and you said the 2015 survey figure is somewhat similar. Is that something to worry about, or is that something to be sanguine about? Obviously, even one life lost is a tragedy and we must do something, we must be more vigilant in terms of ensuring quality and that we don't have spurious or substandard medicines. 'Spurious' is a term that is not commonly used outside of the technical context. So, I'll just switch to 'counterfeiting' and take you on a journey across other industries in India, as a way of answering your question. One out of three auto parts sold in the aftermarket are considered to be counterfeit. These are industry figures. In fast-moving consumer goods, studies have found up to 30% [are counterfeit]. In nutraceuticals, an Assocham study reportedly found 60% to 70%. Pesticide, seeds, and fertilisers, again, 60 to 70%. So, to be very honest, if you tell me that in pharmaceuticals across India – and I'm not talking about the reputed practices in urban centres where ethical and careful doctors may be practising, I'm talking about tier 2, tier 3 towns – the rate of spurious drugs is 0.3%, I would be a little bit sceptical of that, given how widespread counterfeits are in other industries and also given the immense profit margins that unethical bad actors stand to make. In fact, statistics I saw from one of the large pharma companies, among their presentations, said that being a drug counterfeiter can actually be more profitable and lucrative than being a heroin distributor. So that's the kind of profit that people stand to make, and that surely may be a lure for many criminals. So, I don't think we should let the statistics necessarily make us feel good. I would still continue to be very vigilant. But there is some good news. I've been in this industry, looking at this issue right from the 2009 CDSCO report. In 2009, actually, there was a very prominent incident of counterfeit, spurious drugs landing up in Nigeria, marked as 'Made in India'. The question was raised to the Indian government, on why these fake drugs are coming from our country. An investigation was launched and it was found that these drugs never originated from India,

INTERVIEW : Nakul Pasricha Read More »